Protein kinase Cδ oxidation contributes to ERK inactivation in lupus T cells

Arthritis and Rheumatism

Volumn 64, Issue 9, 2012, Pages 2964-2974

  Gorelik, Gabriela J ^a   Yarlagadda, Sushma ^a   Richardson, Bruce C ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C DELTA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL LYSATE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROPORATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LUPUS ERYTHEMATOSUS; MALE; NITRATION; PRIORITY JOURNAL; PROTEIN CONTENT; SIGNAL TRANSDUCTION;

ADULT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN KINASE C-DELTA; T-LYMPHOCYTES;

EID: 84865654244     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34503     Document Type: Article

References (50)

1. Hewagama A, Richardson B,. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33: 3-11.
2. Attwood JT, Yung RL, Richardson BC,. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002; 59: 241-57.
3. Bestor T, Laudano A, Mattaliano R, Ingram V,. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells: the carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 1988; 203: 971-83.
4. Deng C, Yang J, Scott J, Hanash S, Richardson BC,. Role of the ras-MAPK signaling pathway in the DNA methyltransferase response to DNA hypomethylation. Biol Chem 1998; 379: 1113-20.
5. MacLeod AR, Rouleau J, Szyf M,. Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 1995; 270: 11327-37.
6. Rouleau J, MacLeod AR, Szyf M,. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem 1995; 270: 1595-601.
7. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746-56.
8. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC,. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995; 154: 3025-35.
9. Sawalha AH, Jeffries M, Webb R, Lu Q, Gorelik G, Ray D, et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008; 9: 368-78.
10. Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ, et al. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001; 44: 397-407.
11. Lu Q, Wu A, Richardson BC,. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174: 6212-9.
12. Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B,. Impaired T cell protein kinase Cδ activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007; 179: 5553-63.
13. Amos S, Martin PM, Polar GA, Parsons SJ, Hussaini IM,. Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cδ/c-Src pathways in glioblastoma cells. J Biol Chem 2005; 280: 7729-38.
14. Basu A, Tu H,. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ. Biochem Biophys Res Commun 2005; 334: 1068-73.
15. Kuriyama M, Taniguchi T, Shirai Y, Sasaki A, Yoshimura A, Saito N,. Activation and translocation of PKCδ is necessary for VEGF-induced ERK activation through KDR in HEK293T cells. Biochem Biophys Res Commun 2004; 325: 843-51.
16. Zhang Q, Ye DQ, Chen GP, Zheng Y,. Oxidative protein damage and antioxidant status in systemic lupus erythematosus. Clin Exp Dermatol 2010; 35: 287-94.
17. Mansour RB, Lassoued S, Gargouri B, El Gaid A, Attia H, Fakhfakh F,. Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 2008; 37: 103-8.
18. Kurien BT, Scofield RH,. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci 2003; 73: 1655-66.
19. Ahmad R, Rasheed Z, Ahsan H,. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009; 31: 388-96.
20. Pacher P, Beckman JS, Liaudet L,. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies, in SLE,. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
23. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC,. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 2005; 115: 3193-204.
24. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ,. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042-5.
25. Casamayor A, Morrice NA, Alessi DR,. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 1999; 342: 287-92.
26. Knight ZA,. For a PDK1 inhibitor, the substrate matters. Biochem J 2011; 433: e1-2.
27. Morgan PE, Sturgess AD, Davies MJ,. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2069-79.
28. Steinberg SF,. Distinctive activation mechanisms and functions for protein kinase Cδ. Biochem J 2004; 384: 449-59.
29. Kikkawa U, Matsuzaki H, Yamamoto T,. Protein kinase Cδ (PKCδ): activation mechanisms and functions. J Biochem 2002; 132: 831-9.
30. Wu F, Wilson JX,. Peroxynitrite-dependent activation of protein phosphatase type 2A mediates microvascular endothelial barrier dysfunction. Cardiovasc Res 2009; 81: 38-45.
31. Srivastava J, Goris J, Dilworth SM, Parker PJ,. Dephosphorylation of PKCδ by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett 2002; 516: 265-9.
32. Myles T, Schmidt K, Evans DR, Cron P, Hemmings BA,. Active-site mutations impairing the catalytic function of the catalytic subunit of human protein phosphatase 2A permit baculovirus-mediated overexpression in insect cells. Biochem J 2001; 357: 225-32.
33. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF,. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62: 2064-72.
34. Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, et al. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 2007; 16: 195-200.
35. Nagy G, Koncz A, Perl A,. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 2005; 25: 123-40.
36. Khan F, Siddiqui AA, Ali R,. Measurement and significance of 3-nitrotyrosine in systemic lupus erythematosus. Scand J Immunol 2006; 64: 507-14.
37. Nishizuka Y,. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
38. Steinberg SF,. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88: 1341-78.
39. Gorelik GJ, Sawalha AH, Richardson BC,. Lack of PKCδ kinase activity in T cells induces a lupus-like disease [abstract]. Lupus 2010; 19: 7.
40. Nagy G, Koncz A, Telarico T, Fernandez D, Ersek B, Buzas E, et al. Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2010; 12: 210.
41. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS,. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians 1999; 111: 611-21.
42. Rybin VO, Guo J, Sabri A, Elouardighi H, Schaefer E, Steinberg SF,. Stimulus-specific differences in protein kinase Cδ localization and activation mechanisms in cardiomyocytes. J Biol Chem 2004; 279: 19350-61.
43. Denning MF, Dlugosz AA, Threadgill DW, Magnuson T, Yuspa SH,. Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase Cδ. J Biol Chem 1996; 271: 5325-31.
44. 2-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci U S A 2001; 98: 6587-92.
45. Kronfeld I, Kazimirsky G, Lorenzo PS, Garfield SH, Blumberg PM, Brodie C,. Phosphorylation of protein kinase Cδ on distinct tyrosine residues regulates specific cellular functions. J Biol Chem 2000; 275: 35491-8.
46. Kiroycheva M, Ahmed F, Anthony GM, Szabo C, Southan GJ, Bank N,. Mitogen-activated protein kinase phosphorylation in kidneys of βs sickle cell mice. J Am Soc Nephrol 2000; 11: 1026-32.
47. Wayne J, Sielski J, Rizvi A, Georges K, Hutter D,. ERK regulation upon contact inhibition in fibroblasts. Mol Cell Biochem 2006; 286: 181-9.
48. Khan F, Ali R,. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol 2006; 39: 189-96.
49. Webster RP, Roberts VH, Myatt L,. Protein nitration in placenta-functional significance. Placenta 2008; 29: 985-94.
50. Hedrich CM, Tsokos GC,. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med 2011; 17: 714-24.